Erdafitinib (Johnson & Johnson/Otsuka) is a small molecule inhibitor that targets fibroblast growth factor receptors (FGFRs), which play a role in the angiogenesis pathway, facilitating tumor growth and metastasis. FGFRs are activated by mutation and overexpressed in about 10–20% of patients with urothelial bladder cancer. Early-phase studies of erdafitinib in urothelial bladder cancer have demonstrated promising safety and preliminary efficacy in patients with FGFR pathway alterations.
4 PRODUCT PROFILES
4 erdafitinib : Bladder cancer
7 Figure 1: Erdafitinib for urothelial bladder cancer – SWOT analysis
LIST OF FIGURES
8 Figure 2: Datamonitor Healthcare’s drug assessment summary for erdafitinib in urothelial bladder cancer
9 Figure 3: Datamonitor Healthcare’s drug assessment summary for erdafitinib in urothelial bladder cancer
TABLE OF CONTENTS
5 Table 1: Erdafitinib drug profile
6 Table 2: Key erdafitinib Phase II trial in urothelial bladder cancer
6 Table 3: Erdafitinib early-phase data in urothelial bladder cancer
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.